



RESPIRATORY FAILURE IN ACUTE ORGANOPHOSPHATE POISONING: MECHANISMS, RECOGNITION, AND MANAGEMENT

DUMPALA PRAMOD AGASTEEN ¹, MAGATI TEJASWINI ¹, SADEPALLI STELLA SIRISHA ¹, SANGADALA THANVIKA ¹, M. SOWJANYA ², M. BHARGAVI ³, YADALA PRAPURNA CHANDRA ⁴

¹V Year Pharm.D, Ratnam institute of pharmacy, Pidathapolur (V & P), Muthukur (M), SPSR Nellore 524346.

²Assistant Professor, Department of Pharmacy Practice, Ratnam institute of pharmacy, Pidathapolur (V & P), Muthukur (M), SPSR Nellore 524346.

³Associate Professor, Department of Pharmacy Practice, Ratnam institute of pharmacy, Pidathapolur (V & P), Muthukur (M), SPSR Nellore 524346.

⁴Principal And Professor, Department of Pharmacology, Ratnam Institute of Pharmacy. Pidathapolur, (V & P), Muthukur (M), Spsr Nellore District-524 346, Andhra Pradesh.

Abstract

Organophosphate (OP) poisoning is one of the serious health problems globally, especially in the agricultural regions of low, and middle, income countries, and respiratory failure has been identified as the principal cause of death. This review to summarize the main features of pathophysiology, diagnosis, and treatment of respiratory failure caused by OP poisoning. Respiratory failure is the result of the conjunction of multiple mechanisms, such as muscarinic, neuromuscular junction, and central depression. The clinical manifestations can be ranging from acute cholinergic crisis to intermediate syndrome so that the patient has to be carefully monitored and treated as soon as possible. The therapeutic approach involves immediate airway control, use of mechanical ventilation, and administration of atropine and oximes, which are antidotes. Although the pathophysiology of the disease has been well elucidated, the death rate is still high, so it is critical to make an early diagnosis and to administer intensive treatment without delay. This article presents a management protocol for this life-threatening condition currently supported by the existing scientific literature.

Keywords: Organophosphate poisoning, Respiratory failure, cholinergic crisis, Intermediate syndrome, Mechanical ventilation, Atropine and oxime therapy.

*Corresponding Author

M. Sowjanya
Department of Pharmacy Practice
Ratnam institute of pharmacy,
Pidathapolur (V & P), Muthukur (M), SPSR Nellore 524346.

DOI: <https://doi.org/10.22376/ijtos.v4i1.80>

Article History

Received: 11.12.2025

Revised: 24.01.2026

Accepted: 13.02.2026

This article is under the CC BY- NC-ND License (<https://creativecommons.org/licenses/by-nc-nd/4.0>)

Copyright © International Journal of trends in OncoScience, available at www.ijtos.com



I. INTRODUCTION

Organophosphate compounds, commonly used as pesticides and under development as chemical warfare agents, are a major cause of poisoning worldwide. The mechanism of toxicity is primarily due to the irreversible inhibition of acetylcholinesterase (AChE) with a consequent build-up of acetylcholine in cholinergic synapses in the nervous system [1]. The cholinergic crisis that follows can manifest with a variety of muscarinic, nicotinic, and central nervous system symptoms, with respiratory failure being the main cause of death [2].

Respiratory failure in organophosphate poisoning is a complicated clinical issue with several contributing causes and fluctuating time courses. The pathogenesis of respiratory failure in organophosphate poisoning is a complicated phenomenon comprising peripheral airway damage, neuromuscular blockade, and cerebral depression, in contrast to the majority of other toxic situations, where the pathophysiology is dominated by a single cause. Additionally, respiratory failure, also known as intermediate syndrome, can happen in the acute phase within hours of poisoning or even days after the first cholinergic crisis [3].

The goal of this study is to present a thorough and fact-based evaluation of respiratory failure in cases of acute organophosphate poisoning. We want to give doctors useful information to enhance outcomes in this illness by condensing the current understanding of the etiology, clinical diagnosis, and therapeutic approaches [4].

2. EPIDEMIOLOGY AND CLINICAL RELEVANCE

Acute organophosphate pesticide poisoning is a serious clinical issue, particularly in underdeveloped nations where these chemicals are often used in agriculture and emergency medical services may be few. Millions of instances of OP poisoning are recorded annually, and in many places, the case mortality rate is above 15%, indicating the widespread severity of the problem. [5].

The main cause of mortality in cases of OP poisoning is respiratory failure. 24% of patients in a large prospective study of 376 patients in Sri Lanka who had been diagnosed with OP poisoning required endotracheal intubation because of respiratory failure. In a series of patients, the rate of respiratory failure necessitating mechanical ventilation was 52.1%, even among the elderly. High rates of morbidity and death are known to be linked to the requirement for ventilator assistance. [6].

There is a bimodal trend in the occurrence of respiratory failure. In one study, 58% of patients who needed to be incubated experienced severe cholinergic symptoms, decreased awareness, and respiratory failure within 2 hours of hospital admission (median 3–4 hours after intake). However, in 32% of cases, respiratory failure occurred 24 hours after admission (median 64 hours), while the patient was still aware and free of acute cholinergic symptoms, suggesting delayed neuromuscular failure [7].

3. PATHOPHYSIOLOGICAL MECHANISMS OF RESPIRATORY FAILURE

Acute organophosphate (OP) poisoning causes respiratory failure through a complicated interaction between central and peripheral systems. For evidence-based clinical care, these various yet overlapping pathways must be precisely defined.

3.1 Muscarinic Receptor-Mediated Mechanisms

A number of alterations brought on by too much acetylcholine at muscarinic receptors in the secretory glands and airways lead to compromised respiratory function. While excessive gland production causes a copious amount of bronchorrhea, bronchospasm is a contraction of the bronchial smooth muscle. Abnormalities in gas exchange and airway blockage result from these combined consequences. Additionally, laryngospasm may make the upper airways less open [8].

Increased salivation and tearing are additional muscarinic symptoms that contribute to the acute cholinergic crisis's characteristic "wet" appearance. By reducing oxygen supply,

cardiac vagal effects including bradycardia and hypotension can exacerbate respiratory problems. The degree of cholinesterase inhibition directly correlates with the severity of muscarinic symptoms, which are often alleviated by antimuscarinic medications such as atropine [9].

3.2 Nicotinic Receptor-Mediated Mechanisms

A biphasic response is brought on by over stimulating nicotinic receptors at the neuromuscular junction. Muscle weakness and paralysis result from the second depolarizing blockade, whereas fasciculations and spasms are caused by the first stimulation. Hypoventilation and reduced tidal volumes are the outcomes of this, which also applies to the respiratory muscles (diaphragm, intercostals, and accessory muscles).

Aspiration is more frequent when there is weakness in the bulbar muscles, which include the tongue and pharyngeal muscles, which prevent them from protecting the airways. Clinically, proximal limb weakness can be utilized to show that the respiratory muscles are involved because it is frequently noticeable [10].

There is still much to learn about the pathogenesis of delayed nicotinic dysfunction in intermediate syndrome. According to theories, oxidative stress myopathy, skeletal muscle damage from direct OP toxicity, down regulation or desensitization of postsynaptic acetylcholine receptors, inadequate release of postsynaptic acetylcholine, and elevated synaptic acetylcholine levels all contribute to the continuous stimulation of neuromuscular junctions. Depending on the OP chemical, dosage, and patient, the significance of these hypotheses is likely to vary [11].

3.3 Central Respiratory Depression

The impact of OP poisoning on the central nervous system (CNS), particularly during the acute phase of poisoning, is one of the main reasons for respiratory failure after OP overdose. The reduction of breathing activity and loss of respiratory rhythm brought on by brainstem cholinergic stimulation shows up as erratic breathing patterns, a decrease in respiratory rate, and in the worst situations, apnea.

Usually, central respiratory depression is accompanied by unconsciousness, which makes it much harder to secure the airway and raises the danger of aspiration. More people now realize that the central processes control the early phases of respiratory failure, and there is some data that suggests these mechanisms may be more clinically significant than previously believed. [12]

Additional central respiratory function impairment can come from cerebral edema, which can occasionally arise from acute poisoning or hypoxic damage [8]. Peripheral processes and central depression combine to provide a complicated clinical picture that needs careful assessment and treatment [13].

3.4 Additional Contributing Factors

Respiratory compromise in organophosphate (OP) poisoning is caused by several other mechanisms. A common consequence of vomiting, decreased awareness, and compromised airway protective reflexes is aspiration of stomach contents. Common side effects that accelerate respiratory failure and necessitate ongoing mechanical

ventilation include aspiration pneumonitis and subsequent bacterial pneumonia [14].

Severe poisoning may result in acute respiratory distress syndrome (ARDS), which is characterized by anomalies in gas exchange, pulmonary edema, and increased lung weight. Direct pulmonary toxicity, systemic inflammation, and secondary damage from aspiration and infection are considered to represent the pathogenesis of OP-induced ARDS.

One aspect that has been disregarded as a possible cause of respiratory failure is solvent toxicity. Organic solvents used in many commercial OP pesticide formulations have the potential to cause direct pulmonary poisoning, which manifests quickly at first. This damage mechanism differs from cholinergic poisoning and may require special identification and treatment [15].

Lastly, respiratory dysfunction may also be caused by treatment-related issues including atropine toxicity and iatrogenic reasons. Excessive atropinization can cause tachycardia, hyperthermia, and central nervous system stimulation, all of which may worsen respiratory health [16].

4. CLINICAL RECOGNITION AND DIAGNOSIS

For prompt treatment and improved results, respiratory failure in OP poisoning must be identified early. The intensity of exposure, the period of detection, and the dominant toxicity pathway all affect the clinical picture.

4.1 Temporal Patterns of Respiratory Failure

In OP poisoning, respiratory failure manifests as a spectrum of fluctuating and overlapping patterns rather than as two discrete clinical entities within clearly defined time periods. In cases of OP poisoning, three forms of respiratory failure have been extensively documented [17].

1) Abrupt early respiratory failure: characterized by an abrupt cholinergic crisis, this pattern often manifests 2–24 hours after exposure. Patients who exhibit this pattern have both central and peripheral respiratory failure, severe muscarinic and nicotinic symptoms, and impaired mental state. This trend explains around 58% of intubated patients in prospective trials.

2) Patients who appear to have recovered from the acute cholinergic crisis may experience delayed respiratory failure (intermediate syndrome) 24 to 96 hours following exposure. These patients often have little to no cholinergic symptoms and are aware, but they eventually experience increasing respiratory muscle weakening. Approximately 32% of incubated patients follow this trend.

3) Persistent or recurring respiratory failure: After an acute respiratory failure, some patients regain consciousness, but their extubation fails, necessitating care for at least six days. This pattern results from ongoing neuromuscular injury even after the symptoms of a cholinergic crisis have subsided [18].

4.2 Clinical Signs and Symptoms

The clinical manifestations of respiratory failure in OP poisoning include a variety of symptoms that depend on the pathophysiology:

Bradycardia, miosis, lacrimation, bronchospasm with wheezing, excessive salivation and bronchial secretions, urine leakage, and feces are all signs of muscarinic disease. These symptoms are frequently remembered by using acronyms like DUMBELS (Defecation, Urination, Miosis, Bronchospasm/Bronchorrhea, Emesis, Lacrimation, and Salivation) or SLUDGE (Salivation, Lacrimation, Urination, Defecation, Gastrointestinal Irritation, Emesis).

Nicotinic symptoms include weakness, paralysis, and muscular fasciculations, particularly in the neck flexors, proximal limb muscles, and muscles innervated by motor cranial nerves. Hypertension and tachycardia may be symptoms of the first sympathetic ganglionic activation.

Seizures, respiratory depression, and mental state changes ranging from disorientation to coma are all signs of central nervous system disorders. The Glasgow Coma Scale score drops precipitously with severe acute poisoning, even to 3/15.

Respiratory features indicating that respiratory failure is either about to occur or has already occurred include:

- ✓ Difficult and labored breathing
- ✓ Slow breathing (respiratory rate <10 breaths per minute)
- ✓ Abdominal breathing pattern indicating diaphragmatic fatigue
- ✓ Lowered tidal volume (<180 ml per breath)
- ✓ Failure to keep the airway open
- ✓ Cyanosis and hypoxemia
- ✓ Signs of aspiration

A high level of clinical suspicion must be maintained since bradycardia and respiratory distress can occasionally occur without any cholinergic first signs. [19].

4.3 Diagnostic Evaluation

A combination clinical strategy based on history, physical examination, laboratory testing, and monitoring is used to diagnose organophosphate (OP) toxicity and evaluate respiratory failure.

A combination of exposure history, typical clinical appearance, and cholinesterase inhibition test results are used to confirm exposure. Reduced plasma or red blood cell cholinesterase activity to less than 50% of the normal mean is typically indicative of this. Compared to red blood cell acetylcholinesterase activity, butyric cholinesterase (pseudo cholinesterase) activity is more often tested and is associated with clinical severity. In research settings, exposure can be verified by specific OP analyses [20].

Respiratory evaluation includes:

- Continuous pulse oximetry for hypoxemia
- Arterial blood gas analysis showing hypoxemia ($\text{PaO}_2 < 50\text{-}60$ mmHg), hypercapnia ($\text{PaCO}_2 > 50\text{-}55$ mmHg), and respiratory acidosis
- Monitoring of respiratory rate and effort
- Tidal volume measurement if possible

- Clinical assessment of work of breathing and airway patency

Other studies include

Chest roentgenography to identify acute respiratory distress syndrome (ARDS), pneumonia, or aspiration

The results of inflammatory and complete blood count investigations show that systemic ischemia is indicated by high C-reactive protein, which has detrimental prognostic implications.

Serum electrolytes, renal function, and lactate; higher levels of creatinine and lactate have a negative prognostic significance.

Serum albumin has a poor predictive value, and hypoalbuminemia

In patients who have recovered from the acute cholinergic crisis, the strength of the proximal muscles, neck flexor muscles, and respiratory muscles should be particularly monitored for intermediate syndrome during the first four to five days after exposure [21].

5. MANAGEMENT STRATEGIES

A methodical strategy that addresses airway protection, breathing assistance, antidote delivery, decontamination, and management of complications is necessary for the treatment of respiratory failure in OP poisoning [22].

5.1 Initial Resuscitation and Airway Management

Early airway management is critical and should be anticipated given the unpredictable timing and possible rapid progression of respiratory failure. The indications for endotracheal intubation include, but are not limited to:

- ✓ - Reduced level of consciousness with inability to protect the airway
- ✓ - Excessive bronchial secretions leading to airway obstruction
- ✓ - Respiratory rate of less than 10 breaths per minute
- ✓ - Tidal volume of less than approximately 180 mL per breath
- ✓ - Abdominal breathing pattern indicating fatigue of the respiratory muscles
- ✓ - Hypoxemia or increasing PaCO₂ with supplemental oxygen
- ✓ - Evidence of respiratory muscle weakness

To avoid airway blockage and aspiration, aggressive suctioning of secretions is required both before and after intubation. Securing the airway should be tried as soon as feasible due to the potentially fatal course of respiratory collapse.

Additional oxygenation to maintain appropriate oxygenation, intravenous access for fluid resuscitation and drug delivery, and hemodynamic support as necessary are all part of the first resuscitation attempts. Fluid replenishment and isotropic support (dopamine, for instance) may be required in the event of shock [23].

5.2 Mechanical Ventilation

Life-saving mechanical ventilation may be required for extended periods of time. According to one study, endotracheal intubation was used on 24% of the patients, and some ventilator support instances persisted for a few days.

When given supported breathing, patients with intermediate syndrome usually recover in five to eighteen days.

Different ventilator methods have been mentioned in the literatures like:

- ✓ Use of Synchronized Intermittent Mandatory Ventilation (SIMV) at first
- ✓ Downgrading to pressure support ventilation (CPAP) as the patient gets better
- ✓ Extubation based on Spontaneous Breathing Trial (SBT) criteria
- ✓ Employing lung, protective ventilation strategies so as not to get ventilator, induced lung injury, especially in patients with ARDS

Some aspects of mechanical ventilation may include:

- ✓ Management of secretions aggressively with frequent suctioning
- ✓ Preventing and treating ventilator, associated pneumonia
- ✓ Keeping an eye on the complications such as barotraumas and ARDS
- ✓ Getting the patient moving and doing pulmonary rehabilitation at an early stage if possible

The severity of the poisoning, the development of co morbidities, and the restoration of neuromuscular function are all closely correlated with the length of time spent on mechanical breathing. The risk of increased morbidity and death associated with prolonged mechanical breathing highlights the significance of cautious management in the critical care unit. [24].

Oximes (pralidoxime, obidoxime) act as cholinesterase reactivators by breaking the phosphate bond of the inhibited enzyme, thus restoring acetylcholinesterase (AChE) activity.

The regimens include:

- ✓ - Pralidoxime chloride: 1-2 g IV bolus over 4 hours, followed by 1 g every 4-6 hours for 1-3 days
- ✓ - Alternative: continuous infusion following a loading dose
- ✓ - Obidoxime: bolus followed by continuous infusion

Particularly in the prevention and management of intermediate syndrome, the function of oximes is still debatable. Although the precise time limit varies depending on the organophosphate molecule employed, oxides are best utilized early, before the phosphorylated enzyme ages. Additionally, some evidence points to the possibility that intermediate syndrome might result from oxime therapy failure. Despite the lack of solid data supporting their effectiveness, oximes are nonetheless often utilized in clinical practice. Additionally, in most regimens, they are the initial course of treatment. [25].

5.4 Decontamination

Decontamination must be done to prevent systemic toxicity and further absorption:

Dermal decontamination involves washing the skin with soap and water after removing the contaminated clothing.

Gastrointestinal decontamination: If therapy begins within one to two hours of consumption, gastric lavage can be performed; however, there is little proof that this is beneficial.

Activated charcoal: 50, 100 g given via nasogastric tube if the airway is protected.

Protection of healthcare workers: Use of appropriate personal protective equipment to prevent secondary contamination [26].

5.5 Supportive Care and Complications

Without supportive care, it is impossible to have a good outcome:

Management of aspiration and pneumonia: Supportive treatment, active pulmonary toilet, and empirical antibiotic therapy are necessary for the typical consequences of aspiration pneumonitis and subsequent bacterial pneumonia. Steroids and antibiotics were given in a serious pediatric aspiration case.

Management of ARDS: Lung protective breathing techniques are essential for patients with ARDS. Restoring normovolemia and tissue oxygenation should be the primary objectives of fluid management. Excessive fluid administration, on the other hand, may exacerbate pulmonary edema.

Infection control: Septicemia can be a consequence of prolonged ICU stay

Rehabilitation and New Therapies: Physical therapy and respiratory rehabilitation are crucial components of treating individuals with chronic neuromuscular weakness.

Although the literature is mostly made up of case studies, exchange blood transfusion is one of the novel treatments that has been employed as a detoxifying technique in severe pediatric cases. In certain facilities, continuous renal replacement therapy (CRRT) has also been employed, with positive results documented. [27].

6. SPECIAL CONSIDERATIONS

6.1 Intermediate Syndrome (IMS)

A well-known clinical symptom that develops 24 to 96 hours following acute organophosphate (OP) poisoning is called intermediate syndrome (IMS). A primary cause of OP poisoning morbidity and death due to respiratory failure, it is characterized by respiratory muscle weakness in awake individuals without any cholinergic symptoms.

Weakness of the neck flexors, proximal limb muscles, respiratory muscles, and muscles supplied by motor cranial nerves are among the clinical manifestations of IMS. In the context of maintained awareness, patients may exhibit increasing respiratory failure, proximal paralysis of the arms and legs, and an inability to lift the head.

IMS's pathogenesis is not entirely known at this time. Muscle necrosis, oxidative stress myopathy, postsynaptic acetylcholine receptor down regulation or desensitization, chronic acetylcholinesterase inhibition, and failure of postsynaptic acetylcholine release are some of the theories.

The cornerstone of managing IMS is supportive care, and it is crucial to start mechanical ventilation as soon as possible. There is no particular treatment for IMS due to the uncertain pathogenesis, however aggressive decontamination and antidotal therapy may be helpful. With supportive treatment,

a full recovery should occur 5–18 days from the beginning of symptoms.

A positive result requires preventing paralysis of the breathing muscles. To identify IMS early before the beginning of potentially deadly respiratory collapse, careful surveillance is required for four to five days following exposure [28].

6.2 Elderly Patients

The prognosis for elderly people with OP poisoning is worse and they provide a problem. Compared to other age groups, 52.1% of senior patients in one research experienced respiratory failure and needed mechanical ventilation.

Elderly patients with OP poisoning may have:

- Decreased physiological reserve
- Associated diseases affecting the respiratory system
- Differences in pharmacokinetics and pharmacodynamics of antidotes
- Susceptibility to complications

Elderly individuals are more likely to experience respiratory failure and problems due to surgery or therapy, but the therapeutic approach is the same as for younger patients.

6.3 Pediatric Aspects

Depending on the child's size, developmental stage, and the type of exposure, pediatric instances of organophosphate poisoning present a unique set of issues. Aspiration is a complicating complication in the case report of a five-year-old boy who was badly poisoned with chlorpyrifos, raising the likelihood of severe respiratory failure, shock, and coma.

Pediatric patients raise several points for consideration such as:

A collection of antidotes at appropriate weight-based doses Utilizing various breathing techniques and smaller endotracheal tubes Increased oxygen consumption and metabolic rate Increased vulnerability to electrolyte imbalance and dehydration Examining novel treatment modalities, such as exchange transfusion, in situations of high severity. Results and Predictive Elements The results of individuals with respiratory failure brought on by organophosphates vary widely. They are mostly determined by the severity of the poisoning, how quickly treatment is started, and whether the patient experiences any problems. These instances have been linked to fatality rates of over 15%, with respiratory failure accounting for the bulk of deaths.

Positive prognostic factors:

The earliest possible diagnosis and course of action Atropinization with adequate nutrition and oxime treatment The earliest feasible start of mechanical ventilation and airway management Absence of serious side effects (sepsis, acute respiratory distress syndrome [ARDS], aspiration) Young age of the patient adverse prognostic variables:

- ✓ Mechanical ventilation duration was very long
- ✓ The patient developed ARDS or severe pneumonia
- ✓ Hypoalbuminemia
- ✓ Creatinine, lactate, or C, reactive protein levels increase [29].

8. FUTURE DIRECTIONS AND RESEARCH GAPS

Organophosphate (OP) poisoning has a wealth of clinical expertise, however there are still a number of important information gaps and research needs:

Mechanistic insights: More research is still needed to determine the underlying processes of delayed neuromuscular junction dysfunction and intermediate syndrome. Additional investigation on oxidative damage, my toxicity, and receptor desensitization may aid in directing the creation of innovative therapies.

Oxime therapy: There is ongoing debate on the effectiveness of oxime therapy in the prevention and management of respiratory failure, especially in intermediate syndrome. Efficacy and dosing regimens must be thoroughly established by carefully planned randomized controlled trials.

Protection of the central nervous system: Given the significance of central respiratory depression, research into developing CNS-protective strategies seems appealing. There may be therapeutic potential for substances that influence the brainstem's cholinergic circuits [30].

9. CONCLUSION

One of the main side effects of acute organophosphate (OP) poisoning is respiratory failure. There are several variables at play in this complicated clinical issue. The human time course is diverse because numerous pathophysiological mechanisms, such as the muscarinic, nicotinic, and central ones, have been found. These mechanisms occur in a distinct time sequence, beginning with an acute cholinergic crisis and advancing to delayed intermediate syndrome. Early patient identification and aggressive treatment are critical.

Clinical diagnosis necessitates close monitoring for at least four or five days following the exposure event, a high level of awareness on the potential for organophosphate poisoning, and familiarity with the various symptoms. The therapy calls for careful cleaning, the management of sequelae such as aspiration pneumonia and acute respiratory distress syndrome, the prudent use of atropine and oximes as antidotes, and early airway intervention and mechanical ventilation as needed.

Even while the number of instances that result in mortality from respiratory failure caused by organophosphates has been declining, it is still high, particularly in underdeveloped nations where most cases occur and facilities are inadequate. The availability of an intensive care unit to offer mechanical breathing for an extended period of time, early detection and prompt administration of suitable therapy, and the lack of complications are the main criteria that influence survival.

There is still more to be done in the areas of investigating the processes underlying delayed neuromuscular damage, demonstrating the efficacy of oximes, developing neuroprotective techniques for the central nervous system, identifying early biomarkers, testing novel treatments in clinical trials, etc. If the global organophosphate burden is to be considerably decreased, public health intervention measures targeted at exposure reduction and health

improvement are required in addition to clinical care advancements.

10. FUNDING

Nil

11. CONFLICT OF INTEREST

Authors are declared that no conflict of interest

12. ACKNOWLEDGMENT

Authors are thankful to the management of Ratnam Institute of Pharmacy.

13. INFORM CONSENT AND ETHICAL CONSIDERATIONS

Not Applicable

14. REFERENCES

1. Eddleston M, et al. Respiratory failure in acute organophosphorus pesticide self-poisoning. *QJM*. 2006. doi:10.1093/qjmed/hcl065.
2. Tsao TC, et al. Respiratory failure of acute organophosphate and carbamate poisoning. *Chest*. 1990;98(3):631–6. doi:10.1378/chest.98.3.631.
3. Tong-qin, et al. Respiratory failure caused by acute organophosphorus pesticides poisoning: analysis of 56 cases. 2006. doi:10.3969/j.issn.1007-1326.2006.02.029.
4. Giyanwani PR, et al. Respiratory failure following organophosphate poisoning: a literature review. *Cureus*. 2017;9(9):e1651. doi:10.7759/cureus.1651.
5. Hulse EJ, et al. Respiratory complications of organophosphorus nerve agent and insecticide poisoning: implications for respiratory and critical care. *Am J Respir Crit Care Med*. 2014;190(12):1342–54. doi:10.1164/rccm.201406-1150CI.
6. Patil VP, et al. Contributing factors for morbidity and mortality in patients with organophosphate poisoning on mechanical ventilation: a retrospective study in a teaching hospital. *J Clin Diagn Res*. 2016;10(12):OC06–OC09. doi:10.7860/JCDR/2016/22116.9038.
7. Bryant S, et al. Organophosphate poisoning. *Acad Emerg Med*. 2008;15(5):497–8. doi:10.1197/S1069-6563(03)00378-6.
8. Sheng-yang, et al. Cause analysis and clinical countermeasure of respiratory failure in acute organophosphorus pesticide poisoning. 2002. doi:10.3969/j.issn.1671-301x.2002.02.007.
9. Baker DJ. The management of respiratory failure following organophosphate exposure. 1998.
10. Yang CC, Deng JF. Intermediate syndrome following organophosphate insecticide poisoning. *J Chin Med Assoc*. 2007;70(11):467–72. doi:10.1016/S1726-4901(08)70043-1.
11. Shin YH, et al. Respiratory failure of acute organophosphate insecticide intoxication. *Tuberc Respir Dis*. 1999;46(3):363–72. doi:10.4046/TRD.1999.46.3.363.

12. Carey JL, et al. Central respiratory failure during acute organophosphate poisoning. *Respir Physiol Neurobiol.* 2013;189(2):403–10. doi:10.1016/j.resp.2013.07.022.
13. Guo-biao, et al. Treatment by mechanical ventilation for respiratory failure caused by acute organophosphorus pesticide poisoning. 2005. doi:10.3969/j.issn.1672-3619.2005.03.023.
14. Trancart MM, et al. Identification of mechanisms underlying ventilatory dysfunction in organophosphorus chemical warfare agent-exposed mice. *Chem Biol Interact.* 2025;403:111713. doi:10.1016/j.cbi.2025.111713.
15. Yu JH, et al. Outcomes of elderly patients with organophosphate intoxication. *Sci Rep.* 2021;11:12431. doi:10.1038/s41598-021-91230-2.
16. Lü M, et al. Experience of the treatment on 35 cases of acute organophosphorus pesticide poisoning complicated with respiratory failure. 2008. doi:10.3969/j.issn.1002-221x.2008.06.009.
17. Lingyun, et al. Analysis of 42 cases of acute organophosphorus pesticide poisoning with respiratory failure. 2014. doi:10.3969/j.issn.1674-4500.2014.04.09.
18. Owobu AC, et al. Severe organophosphate poisoning and aspiration pneumonitis treated with exchange blood transfusion: a case report. *Oxf Med Case Reports.* 2025;2025(1):omaf031. doi:10.1093/omcr/omaf031.
19. Zellner T, et al. Severe pirimiphos-methyl intoxication: clinical findings and cholinesterase status. *Front Pharmacol.* 2022;13:1102160. doi:10.3389/fphar.2022.1102160.
20. Hulse EJ, et al. Organophosphorus nerve agent poisoning: managing the poisoned patient. *Br J Anaesth.* 2019;123(4):457–63. doi:10.1016/j.bja.2019.04.061.
21. Khan S, et al. Prolonged intermediate syndrome due to organophosphate poisoning. *J Clin Toxicol.* 2012;2(3):229. doi:10.4172/scientificreports.229.
22. Singh G, Khurana D. Neurology of acute organophosphate poisoning. *Neurol India.* 2009;57(2):119–25. doi:10.4103/0028-3886.51277.
23. Chong-tao. Analysis of acute organophosphorus pesticide poisoning complicated with respiratory failure: 69 cases. 2012. doi:10.3969/j.issn.1671-8194.2012.36.025.
24. Vamsi V, SomaSekhar K, Sandeep R, Meghana B, Sharmila S. Case Report on Pulmonary mucormycosis. *International Journal of Health Care and Biological Sciences.* 2023 Nov 25:7-9.
25. Azazh A. Severe organophosphate poisoning with delayed cholinergic crisis, intermediate syndrome and organophosphate-induced delayed polyneuropathy. *Ethiop J Health Sci.* 2011;21(3):203–8. doi:10.4314/ejhs.v21i3.
26. Ramadori G. Organophosphorus poisoning: acute respiratory distress syndrome and cardiac failure as cause of death in hospitalized patients. *Int J Mol Sci.* 2023;24(7):6658. doi:10.3390/ijms24076658.
27. Jokanović M, Kosanović M. Neurotoxic disorders and medical management of patients poisoned with organophosphorus pesticides. *Scripta Med.* 2012;43(2):91–7. doi:10.5937/scriptamed1202091j.
28. Anjana S, et al. Predictors of respiratory failure in acute organophosphorus compound poisoning. *Int J Health Res Medico-Legal Pract.* 2019;5(1):23–6. doi:10.31741/IJHRMLP.V5.I1.2019.5.
29. Abdollahi M, Karami-Mohajeri S. Intermediate syndrome caused by organophosphate poisoning: a comprehensive review. *Toxicol Appl Pharmacol.* 2012;258(3):309–14. doi:10.1016/j.taap.2011.11.014.
30. Peter JV, et al. Management of acute organophosphorus pesticide poisoning. *Lancet.* 2008;371(9612):597–607. doi:10.1016/S0140-6736(08)60947-2.